Allergic Bronchopulmonary Aspergillosis Therapeutics Market Will Grow at a 5.3% CAGR by 2030: Growth Plus Reports
Newark, New Castle, USA, March 22, 2023 (GLOBE NEWSWIRE) -- The Global Allergic Bronchopulmonary Aspergillosis Therapeutics Market is expected to grow at a CAGR of 5.3% from 2022 to 2030, owing to rising prevalence respiratory disorders and presence of a strong product pipeline.
The primary factor for the global allergic bronchopulmonary aspergillosis therapeutics market growth is the increased prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pneumonia. According to the National Center for Biotechnology Information, allergic bronchopulmonary aspergillosis (ABPA) affects about 4 million people globally. The presence of a strong product pipeline for allergic bronchopulmonary aspergillosis is another important element driving the expansion of the global market. The total investment in R&D to create new medications to treat aspergillosis has increased. For the development of new pharmaceuticals, the key market players are also implementing strategies like partnering and acquisition, boosting the growth of the global market. Similarly, the ongoing introduction of new treatments and growing public awareness of the need to treat allergic bronchopulmonary aspergillosis promote global market expansion.
The global allergic bronchopulmonary aspergillosis therapeutics market has been analyzed from three perspectives – drug class, route of administration, and region.
Request Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/allergic-bronchopulmonary-aspergillosis-therapeutics-market/8072
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Scope
CAGR of 5.3% from 2022 to 2030
Base year for estimation
Drug Class, Route of Administration, and Region.
North America, Europe, Asia Pacific, and the Rest of the World (ROW)
Excerpts from ‘By Drug Class Segmentation’
Based on drug class, the global allergic bronchopulmonary aspergillosis therapeutics market is divided into:
The corticosteroids hold the largest market share of the global market in 2021. The major therapy for allergic bronchopulmonary aspergillosis is systemic corticosteroids. Additionally, by helping to relieve symptoms, reduce airflow obstructions, lower serum IgE, and lower peripheral blood eosinophil levels, steroids help to increase the demand for corticosteroids. Additionally, it prevents irreversible lung injury and eliminates pulmonary inflammation and infiltrates, promoting segment growth. The corticosteroids for allergic bronchopulmonary aspergillosis therapeutics market is growing since corticosteroids are the first-line therapy for allergic bronchopulmonary aspergillosis in cystic fibrosis and asthma.
Excerpts from ‘By Route of Administration Segmentation’
Based on the route of administration, the global allergic bronchopulmonary aspergillosis therapeutics market is segmented into:
The oral allergic bronchopulmonary aspergillosis therapeutics segment occupied the largest revenue share in 2021. Given that it is the primary form of treatment for ABPA, oral portions account for a significant share. Oral prednisone, itraconazole, and voriconazole are widely recommended as the first line of therapy along with corticosteroid usage because they reduce inflammation, diminish fungal burden, and act as steroid-sparing agents.
Excerpts from ‘By Region Segmentation’
Based on region, the global allergic bronchopulmonary aspergillosis therapeutics market has been segmented into:
Rest of the World
North America dominated the global allergic bronchopulmonary aspergillosis therapeutics market in 2021. The increased frequency of respiratory disorders such as cystic fibrosis and asthma can be ascribed to a significant share of North America. Additionally, the presence of major market players and the developed healthcare system contribute to the North America allergic bronchopulmonary aspergillosis therapeutics market growth. The well-established biotech and pharma enterprises, as well as increased R&D investment, are fueling the regional market growth. The government organizations in the area are raising awareness about aspergillosis treatment, which is anticipated to spur regional growth.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/allergic-bronchopulmonary-aspergillosis-therapeutics-market/8072
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global allergic bronchopulmonary aspergillosis therapeutics market are:
Johnson & Johnson
Merck & Co. Inc.
Astellas Pharma US Inc.
Gilead Sciences Inc.
Regeneron Pharmaceuticals Inc.
Table of Content
Timeline Under Consideration
Historical Years – 2020
Base Year – 2021
Forecasted Years – 2022 to 2030
Currency Used in the Report
Data Collection Methodology
Market Estimation Approach
Market Forecasting Model
Limitations and Assumptions
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2021)
GLOBAL ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
GLOBAL ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8072
VALUE PROPOSITIONS RELATED TO THE REPORT:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
Distributor Landscape Assessment
Customer Base Assessment
Investment & Initiatives Analysis
'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse related reports:
Virus-like Particles Market by Type (Vaccines, Therapeutics), Source (Yeast, Plant, Insect Cell), Application (Hepatitis, Gaucher Disease) - Global Outlook and Forecast 2023-2031 by Type (Vaccines, Therapeutics), Source (Yeast, Plant, Insect Cell), Application (Hepatitis, Gaucher Disease) - Global Outlook and Forecast 2023-2031
Scleral Lens Market by Type (Mini Scleral Lens and Large Scleral Lens), Application (Ocular Surface Disease, Irregular Cornea), and End User (Hospitals, Eye Clinics) - Global Outlook & Forecast 2023-2031
Steam Autoclave Market by Product Type (Tabletop Autoclaves, Vertical Steam Autoclaves), End-user (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies) – Global Outlook & Forecast 2023-2031
RNase and DNase Free Pipette Tips Market by Volume (10 µL, 200 µL), End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes) - Global Outlook and Forecast 2023-2031
Periodontal Therapeutics Market by Drug Type (Antibiotics, Antiseptics) and End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2023-2031
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: email@example.com 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/